United States Patent 11,986,469: Niraparib Prostate Cancer Claims, Patent Scope, and Generic Entry Risk
United States Patent No. 11,986,469 is a narrow but commercially significant method-of-treatment patent directed to niraparib in antiandrogen-resistant prostate cancer. Its principal protection covers administering niraparib to patients with metastatic castration-resistant prostate cancer who either are not BRCA deficient or carry specified DNA-repair abnormalities, including alterations in FANCA, PALB2, CHEK2, BRIP1, HDAC2, and ATM.
The patent does not claim niraparib as a compound, a formulation, or a manufacturing process. It claims clinical use. The strongest commercial exposure is therefore tied to niraparib products marketed for prostate cancer, particularly use in the post-androgen-receptor-pathway-inhibitor and post-taxane settings.
What does United States Patent 11,986,469 protect?
The independent claims protect two related treatment methods.
| Claim |
Core limitation |
Commercial significance |
| 1 |
Treating antiandrogen-resistant prostate cancer with niraparib in a patient who is not BRCA deficient or carries a specified DNA-repair anomaly |
Principal treatment claim |
| 21 |
Determining the patient’s BRCA or DNA-repair status and administering niraparib |
Diagnostic-selection and treatment claim |
| 22 |
Determining eligibility, selecting the patient, and administering niraparib to a patient with antiandrogen-resistant prostate cancer |
Most explicit biomarker-directed claim |
The claims cover niraparib or a pharmaceutically acceptable salt. They do not require a particular salt, excipient, tablet composition, treatment duration, or combination partner.
The principal protected patient population is defined by two alternative pathways:
- The patient is not BRCA deficient; or
- The patient carries at least one DNA-repair anomaly in FANCA, PALB2, CHEK2, BRIP1, HDAC2, or ATM.
The use of "or" materially broadens claim 1. A patient may fall within the claim without carrying one of the listed gene alterations if the patient is not BRCA deficient.
How broad is the niraparib prostate cancer treatment scope?
The treatment claim is broad in drug identity but narrow in disease setting and patient selection.
Drug limitation
The claims cover:
- Niraparib;
- Niraparib salts; and
- A pharmaceutically acceptable amount of niraparib.
They do not expressly require niraparib monotherapy. A product administered with abiraterone, prednisone, an androgen-receptor inhibitor, chemotherapy, or another therapy could potentially fall within the claim if the claimed niraparib administration and patient criteria are satisfied.
The absence of a combination limitation is important. A niraparib-containing combination can implicate the patent even if the commercial regimen contains other active ingredients.
Disease limitation
The claims require prostate cancer that is antiandrogen resistant. Dependent claims narrow the disease to:
- Castration-resistant prostate cancer, or CRPC; and
- Metastatic castration-resistant prostate cancer, or mCRPC.
Claims 2 and 3 are narrower than claim 1. Claim 3 is commercially important because most late-stage niraparib prostate cancer development has focused on mCRPC.
Prior-treatment limitations
Claims 7, 8, 12, 13, 17, and 18 add prior-treatment requirements. The patient may have received:
- At least one line of taxane-based chemotherapy; or
- At least one line of therapy based on enzalutamide, apalutamide, or abiraterone acetate.
These claims target heavily pretreated patients and may correspond to later-line treatment pathways. They are narrower than claim 1 but may be easier to enforce against a label that expressly identifies the same treatment history.
What dosage forms and dosing regimens are protected?
The patent covers a dosage range from approximately 30 mg to approximately 400 mg of niraparib per day.
| Claim |
Dose or dosage-form limitation |
| 4 |
Approximately 30 mg to approximately 400 mg per day |
| 5 |
Approximately 300 mg per day |
| 6 |
Oral administration once daily in 100 mg niraparib dosage forms |
| 10-11 |
Same dose limitations for patients with listed DNA-repair anomalies |
| 15-16 |
Same dose limitations for patients who are not BRCA deficient |
The 300 mg daily limitation is commercially consequential because it corresponds to the standard adult niraparib dose historically used in several indications, subject to product labeling and patient-specific dose modification.
Claim 6 is narrower than claim 5 because it requires:
- Oral administration;
- Once-daily dosing; and
- 100 mg niraparib oral dosage forms.
A generic product with 100 mg tablets and labeling that directs 300 mg once daily could create substantial claim exposure if the approved indication also satisfies the prostate-cancer and biomarker limitations.
The patent does not appear, from the supplied claims, to protect a specific tablet coating, excipient system, particle-size distribution, polymorph, capsule shell, or release profile.
Which biomarker populations fall within the claims?
The claims use a broad negative BRCA condition and a positive list of DNA-repair genes.
BRCA-negative or non-BRCA-deficient population
Claims 1, 14, 15, 16, 17, and 18 cover patients who are "not BRCA deficient." That phrase may include patients who:
- Have no qualifying BRCA1 or BRCA2 deficiency;
- Test negative for a defined BRCA alteration;
- Have a BRCA result that does not meet the applicable deficiency threshold; or
- Lack a BRCA-deficiency classification under the relevant assay.
The precise meaning may depend on the specification, prosecution history, assay methodology, and claim-construction record. The phrase is broader than a positive BRCA mutation requirement and creates potential overlap with patients selected for other homologous-recombination repair abnormalities.
Listed DNA-repair genes
The positive biomarker group includes:
- FANCA;
- PALB2;
- CHEK2;
- BRIP1;
- HDAC2; and
- ATM.
Claim 9 separately recites this gene group. Claims 19 and 20 further address genomic lesions, including:
- Homozygous deletion;
- Heterozygous deletion plus a deleterious mutation;
- Copy-neutral loss of heterozygosity plus a deleterious mutation; and
- A mono-allelic deleterious mutation in the kinase catalytic domain.
These limitations are technically significant. They indicate that the patent is directed not merely to a positive sequencing result but to defined genomic events and, for some genes, particular mutation architectures.
What is the scope of the diagnostic-selection claims?
Claim 21 requires determining whether the patient:
- Is not BRCA deficient; or
- Carries a listed DNA-repair anomaly.
The claim then depends on claim 1’s treatment method.
Claim 22 is a separate independent method claim. It expressly requires:
- Determining the relevant BRCA or DNA-repair status;
- Administering niraparib to the selected patient; and
- Treating antiandrogen-resistant prostate cancer.
These claims are designed to reach biomarker-directed clinical practice. They may be implicated by a treatment protocol in which a healthcare provider or integrated clinical organization performs genomic testing and administers niraparib based on the result.
The diagnostic claims are narrower than a claim covering treatment of all antiandrogen-resistant prostate cancer, but they may provide an alternative infringement theory when the treatment pathway includes documented biomarker testing.
When does United States Patent 11,986,469 lose exclusivity?
The patent issued on May 21, 2024. Its term is generally measured from the applicable nonprovisional or international filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension.
The public patent record should be checked for the precise expiration date and any patent-term adjustment. Based on the apparent 2017 priority period associated with this prostate-cancer niraparib development, the base term is expected to extend into approximately 2038, before any adjustment.
| Event |
Date or period |
| Patent grant |
May 21, 2024 |
| Expected base term |
Approximately 2038, subject to the effective filing date |
| Patent-term adjustment |
Must be confirmed in the USPTO record |
| Patent-term extension |
No extension should be assumed without an FDA-related determination |
Patent expiration does not by itself establish the date for generic entry. Entry may occur earlier if a generic applicant prevails in Paragraph IV litigation, obtains a covenant not to sue, reaches a settlement, or uses a non-infringing label.
What is the FDA and Orange Book status relevant to this patent?
Niraparib is marketed by GSK as Zejula. The FDA approved Zejula for certain ovarian, fallopian tube, and primary peritoneal cancers. Niraparib is also present in Akeega, a fixed-dose combination of niraparib and abiraterone acetate, approved with prednisone for certain adult patients with BRCA-mutated mCRPC.
The FDA-approved prostate-cancer use for Akeega is materially narrower than the supplied claims because the claims reach patients who are not BRCA deficient and patients with alterations in genes beyond BRCA1 and BRCA2.
The regulatory distinction matters:
| Issue |
Patent claim scope |
FDA commercial position |
| Niraparib use |
Antiandrogen-resistant prostate cancer, including non-BRCA-deficient patients |
Approval depends on the specific niraparib-containing product and indication |
| Biomarkers |
BRCA-negative status or listed DNA-repair anomalies |
Akeega approval is associated with a defined BRCA-mutated mCRPC population |
| Drug form |
Niraparib or salt |
Product-specific labeling applies |
| Dose |
Approximately 30-400 mg/day, including 300 mg/day |
FDA label controls approved dosing |
| Combination |
No express exclusion of combinations |
Akeega combines niraparib with abiraterone acetate |
A patent can be relevant to a method outside the current FDA label. Conversely, an Orange Book listing must correspond to an approved drug product and an approved method of use. The presence of Patent 11,986,469 in the Orange Book, its use code, and its relationship to Zejula or Akeega should be confirmed in the current FDA Orange Book and applicable patent-listing submissions.
What Paragraph IV risks exist for generic niraparib?
A generic applicant seeking approval for niraparib could face several pathways.
Paragraph IV certification
A Paragraph IV certification could challenge the validity or enforceability of the patent or assert non-infringement. Potential grounds may include:
- Anticipation by clinical-trial disclosures or prior publications;
- Obviousness based on PARP inhibition, prostate-cancer treatment, and DNA-repair biomarkers;
- Lack of written description for the full gene list or non-BRCA population;
- Lack of enablement across the claimed patient population;
- Indefiniteness of terms such as "not BRCA deficient," "antiandrogen resistant," or "DNA repair anomaly";
- Failure to satisfy the statutory requirements for method-of-treatment claims; and
- Non-infringement based on a label that omits the claimed prostate-cancer use or biomarker selection.
A Paragraph IV filing would not automatically establish a right to launch. Litigation, a 30-month stay, settlement terms, and the approved label would control the practical outcome under the Hatch-Waxman framework.
Section VIII carve-out
A generic applicant could seek a skinny label that excludes the patented prostate-cancer use. This strategy would be more difficult if:
- The reference product’s label includes the claimed indication;
- The generic label retains language directing treatment of antiandrogen-resistant mCRPC;
- The label identifies the listed gene alterations;
- The label recommends 300 mg once-daily dosing for the claimed population; or
- Promotional conduct supplies evidence of induced infringement.
A label limited to non-prostate indications would reduce direct method-of-use risk, although it would not eliminate all possible inducement or contributory-infringement theories.
How strong is the patent estate?
The patent has meaningful commercial value but a narrower legal position than a compound or formulation patent.
Strengths
- The independent claims cover a clinically defined use of niraparib.
- The claims reach a broad non-BRCA-deficient population.
- The specified gene list extends beyond BRCA1 and BRCA2.
- The claims include mCRPC, prior androgen-receptor-pathway therapy, and prior taxane treatment.
- Claims 21 and 22 capture biomarker-directed treatment workflows.
- The 300 mg daily regimen and 100 mg oral dosage forms align with commercially recognizable dosing.
Vulnerabilities
- The patent does not prevent manufacture or sale of niraparib for unrelated approved indications.
- The disease and biomarker terminology may require substantial claim construction.
- "Not BRCA deficient" may create disputes over assay thresholds and clinical interpretation.
- The gene list may face written-description or enablement challenges if the specification does not support each claimed gene and genomic-lesion architecture.
- Clinical publications associated with PARP inhibitors and mCRPC could provide obviousness references.
- A generic may avoid the claims through a non-prostate label or by omitting biomarker-directed language.
- The claims do not protect a distinctive formulation or manufacturing process.
Overall, the estate is strongest against a product label that expressly directs niraparib treatment for antiandrogen-resistant mCRPC at approximately 300 mg once daily in biomarker-defined patients. It is weaker against off-label use, non-prostate indications, and products with a carefully carved-out label.
What litigation and settlement issues affect generic entry?
No litigation, Paragraph IV notice, or settlement agreement can be inferred from the claim text alone. The relevant enforcement record would include:
- Any Hatch-Waxman complaint filed after a Paragraph IV notice;
- ANDA applicants named as defendants;
- Preliminary-injunction or claim-construction rulings;
- Federal Circuit decisions;
- Covenants not to sue;
- Authorized-generic arrangements; and
- Settlement dates and permitted launch dates.
A settlement could permit entry before the nominal 2038 expiration date. Conversely, a successful infringement action could delay entry until expiration or a negotiated date.
The highest-risk generic scenario is a label that directs use in mCRPC after enzalutamide, abiraterone, apalutamide, or taxane therapy and recommends biomarker testing for the listed DNA-repair genes. A lower-risk scenario is a label limited to an unrelated ovarian-cancer indication with the prostate-cancer use carved out.
How does Patent 11,986,469 compare with other niraparib and PARP-inhibitor rights?
Patent 11,986,469 occupies the method-of-use segment of the estate.
| Patent category |
Typical protected subject matter |
Relevance to 11,986,469 |
| Compound patents |
Niraparib chemical structure and salts |
Separate, generally earlier-expiring protection |
| Formulation patents |
Tablets, capsules, release systems, excipients, polymorphs |
Not claimed in the supplied claims |
| Manufacturing patents |
Synthetic routes and intermediates |
May create independent supply-chain barriers |
| Broad oncology-use patents |
PARP inhibition in cancer |
Potential prior-art or overlapping rights |
| Biomarker patents |
Treatment based on HRR or DNA-repair alterations |
Potentially overlapping patient-selection rights |
| Combination patents |
Niraparib with abiraterone, prednisone, or androgen-receptor therapy |
Relevant to Akeega and combination products |
| Patent 11,986,469 |
Niraparib treatment of antiandrogen-resistant prostate cancer in defined biomarker populations |
Product-specific late-life-cycle protection |
Biosimilar risk is not applicable in the ordinary sense because niraparib is a synthetic small molecule, not a biologic. The relevant competitors are generic ANDA applicants, authorized generics, and potentially alternative PARP inhibitors such as olaparib, rucaparib, and talazoparib.
What revenue exposure does the patent create?
The patent’s revenue exposure depends on whether niraparib is commercialized for:
- Monotherapy in prostate cancer;
- Combination therapy with abiraterone;
- Biomarker-selected mCRPC;
- Later-line treatment after taxane chemotherapy; or
- Treatment after enzalutamide, apalutamide, or abiraterone.
The broadest exposure comes from the non-BRCA-deficient language. The commercial exposure is narrower if the marketed product is limited to a BRCA-mutated indication, because much of the claimed population would not appear on the approved label.
For a generic applicant, the principal risk is not simply selling niraparib. It is selling niraparib with labeling, prescribing information, promotional materials, or distribution practices that direct use in the claimed prostate-cancer population.
Key Takeaways
- Patent 11,986,469 is a method-of-treatment patent for niraparib in antiandrogen-resistant prostate cancer.
- The core population is patients who are not BRCA deficient or who carry FANCA, PALB2, CHEK2, BRIP1, HDAC2, or ATM abnormalities.
- The patent reaches CRPC and mCRPC, including patients previously treated with taxanes or androgen-receptor-pathway agents.
- Claims cover approximately 30-400 mg/day and specifically protect 300 mg once-daily oral dosing in 100 mg dosage forms.
- The patent does not claim niraparib’s chemical structure, formulation, or manufacturing process.
- Claims 21 and 22 create additional exposure for biomarker-directed testing and treatment workflows.
- A Paragraph IV challenge would likely focus on obviousness, enablement, written description, claim definiteness, and label-based non-infringement.
- Biosimilar litigation is not the relevant framework. Generic ANDA litigation and Section VIII label carve-outs are the principal entry mechanisms.
- The expected base term appears to extend into approximately 2038, subject to confirmation of the effective filing date, patent-term adjustment, terminal disclaimers, and any regulatory extension.
- The strongest infringement scenario involves a label directing 300 mg once-daily niraparib for biomarker-defined antiandrogen-resistant mCRPC.
FAQs About U.S. Patent 11,986,469
Does Patent 11,986,469 cover Akeega?
Potentially, depending on the approved indication, patient population, dosing, and labeling. The claims do not exclude combination therapy, but the supplied claims do not expressly require abiraterone or prednisone.
Does the patent require a BRCA mutation?
No. Claim 1 covers patients who are not BRCA deficient. It also separately covers patients with specified DNA-repair anomalies.
Is niraparib monotherapy required?
No. The claims require administration of niraparib but do not expressly require that niraparib be administered alone.
Can a generic launch niraparib before the patent expires?
Possibly, through a successful Paragraph IV challenge, a settlement, a non-infringing label, a Section VIII carve-out, or a license. A launch carrying the claimed prostate-cancer indication would present the greatest risk.
Does the patent protect 100 mg niraparib tablets generally?
No. Claim 6 protects use of 100 mg oral dosage forms in a specific once-daily treatment regimen for the claimed prostate-cancer population. It is not a standalone tablet-composition claim.
References
- United States Patent and Trademark Office. (2024). U.S. Patent No. 11,986,469, methods of treating prostate cancer using niraparib.
- U.S. Food and Drug Administration. (2024). Zejula (niraparib) prescribing information.
- U.S. Food and Drug Administration. (2024). Akeega (niraparib and abiraterone acetate) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and patent certifications under the Hatch-Waxman Amendments.
